Phase II trial of transcatheter arterial chemoembolization [cisplatin] (TACE) plus oral sorafenib (BAY 43-9006, Nexavar) for unresectable hepatocellular carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 30 Dec 2016
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin
- Indications Liver cancer
- Focus Therapeutic Use
- 07 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Dec 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 02 Jun 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov